Get started
Work

Adherence to recommended antiviral treatment guidelines for COVID-19 and influenza during pregnancy

Year: 2026
Type: article
Abstract: Infection with SARS-CoV-2 or influenza during pregnancy increases the risk of severe disease, hospitalization, and adverse perinatal outcomes.1,2 Antiviral treatment is recommended for both infections during pregnancy: ritonavir-boosted nirmatrelvir (NMV/r) (Paxlovid) for mild-to-moderate COVID-193 and oseltamivir (Tamiflu) for influenza.4 Despite these clinical recommendations, outpatient treatment for COVID-19 during pregnancy remains suboptimal.5 It is unclear how COVID-19 treatment rates compare with influenza, and whether rates are driven by clinician prescribing or patient acceptance.
DOI: 10.1016/j.ajog.2026.03.005
Authors: Annette K. Regan, Stacey L. Rowe, Jesse Birchfield, Jingxin Liu, Michael J. Fassett, Darios Getahun, Sara Y. Tartof, Stanley Xu
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,410
Funders: Pfizer, Moderna, Seqirus, National Institutes of Health, Centers for Disease Control and Prevention, Johnson and Johnson, National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development
OpenAlex ID: W7138353076
FWCI:
Cites: 4
Cited by:
Related to: 10